Explore By Subject Area   
Return Home
Menu

Lead Webcast

Developing a PD1-VEGFR2 Bifunctional Antibody and Advice for First-in-Class Value

Developing a PD1-VEGFR2 Bifunctional Antibody and Advice for First-in-Class Value

Ottimo Pharma CEO David Epstein shares the potential benefits of a PD1-VEGFR2 bifunctional antibody, what drew him to the organization, and advice for understanding the value of first-in-class therapeutics.

Read More

Featured Videos & Webcasts

Navigating Immuno-Oncology Drug Development in a Saturated Field

Read More

China to West: Deals Shaping the Immuno-Oncology Landscape

Read More

What to Expect at the 2025 IO360° Summit

Read More

Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data

Read More

More Related Content

Videos & Webcasts

How T Cell Engagers Could Provide a Treatment Option for Immunologically Cold or Unresponsive Tumors

How T Cell Engagers Could Provide a Treatment Option for Immunologically Cold or Unresponsive Tumors
Developing Anti-TIGIT Antibodies to Enhance the Body's Response to Cancer

Developing Anti-TIGIT Antibodies to Enhance the Body's Response to Cancer
Immuno-Oncology Debate on Solving Cancer’s Top Challenges

Immuno-Oncology Debate on Solving Cancer’s Top Challenges
Understanding TGF-Beta's Role in Tumor Growth and Targeting to the Right Tumor

Understanding TGF-Beta's Role in Tumor Growth and Targeting to the Right Tumor
A Taste of the IO360º Experience

A Taste of the IO360º Experience
Developing a Neoantigen-Directed Cancer Vaccine with Gritstone Bio

Developing a Neoantigen-Directed Cancer Vaccine with Gritstone Bio
Breakthroughs in Systemic Immunotherapy using a Novel Drug Delivery System

Breakthroughs in Systemic Immunotherapy using a Novel Drug Delivery System
Crafting and Telling Your Leadership Story

Crafting and Telling Your Leadership Story
Taking Lessons from the Last Decade of IO to Develop the Next Wave of Therapeutics

Taking Lessons from the Last Decade of IO to Develop the Next Wave of Therapeutics
The Personal Impact of a Cancer Immunotherapy Trial

The Personal Impact of a Cancer Immunotherapy Trial
Using AI to Accelerate the Next Generation of Oncology Immunotherapies

Using AI to Accelerate the Next Generation of Oncology Immunotherapies
Dr Kristen Hege Looks Back at Lessons Learned from a Career in CAR-T Therapy

Dr Kristen Hege Looks Back at Lessons Learned from a Career in CAR-T Therapy
Targeting Clonal Tumor Neoantigens and their Key Role in Immune Response

Targeting Clonal Tumor Neoantigens and their Key Role in Immune Response
Fireside Chat: The Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity

Fireside Chat: The Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity
Nobel Laureate Keynote: Bioorthogonal and Click Chemistries’ Impact on Advancing Immuno-Oncology

Nobel Laureate Keynote: Bioorthogonal and Click Chemistries’ Impact on Advancing Immuno-Oncology
The Patient Story: The Incredible Immunotherapy That Gave Him Back His Life

The Patient Story: The Incredible Immunotherapy That Gave Him Back His Life
Biotech CEO Leadership on the Business and Science of Cell and Gene Therapy

Biotech CEO Leadership on the Business and Science of Cell and Gene Therapy
Regulatory Opportunities to Accelerate the Development of Cell Therapies

Regulatory Opportunities to Accelerate the Development of Cell Therapies
Priming the Immune System to Provoke Checkpoints and Maintain the Immunotherapy Momentum

Priming the Immune System to Provoke Checkpoints and Maintain the Immunotherapy Momentum
How MD Anderson is Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

How MD Anderson is Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
How Synthetic Biology & Synthetic Circuits In Cell Therapy Can Advance the Field

How Synthetic Biology & Synthetic Circuits In Cell Therapy Can Advance the Field
Dr Arie Belldegrun Discusses His Vision for Treating Cancer

Dr Arie Belldegrun Discusses His Vision for Treating Cancer

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.